Risa Tomioka-Inagawa
Papers
2
Total Citations
8
H-Index
2
About
Risa Tomioka-Inagawa is a Japanese urologic surgeon and researcher whose work focuses on advancing treatment strategies for high-risk prostate cancer and refining surgical training for complex robotic procedures. Her major contributions lie in evaluating novel neoadjuvant chemohormonal therapies and developing structured educational frameworks for robot-assisted radical cystectomy (RARC). In her most-cited study (5 citations), she retrospectively assessed the efficacy and safety of combining a luteinizing hormone-releasing hormone (LHRH) antagonist with tegafur-uracil (UFT) for high-risk prostate cancer, offering early evidence for a potentially less toxic neoadjuvant regimen. Her second influential paper (3 citations) introduces the “Trisection Method” training system, which divides RARC with intracorporeal urinary diversion into three distinct phases to enhance surgeon concentration, reduce fatigue, and systematically train young surgeons—a practical innovation with implications for surgical education in Japan and beyond. While her citation counts are modest, her work addresses critical gaps in both oncologic management and surgical pedagogy, demonstrating a dual commitment to improving patient outcomes and the next generation of urologic surgeons. Her research is particularly relevant for clinicians exploring neoadjuvant options for high-risk prostate cancer and institutions seeking structured robotic training protocols.
Research Focus
Key Achievements
Top Papers
- 1
- 2